IRVINE, Calif., Oct. 1, 2012 /PRNewswire/ -- Syneron Medical
Ltd. (NASDAQ: ELOS), www.syneron.com, the global leader in medical
aesthetic products and technology, today kicked its new Break Up.
Get Even! Campaign for its award winning elure™ product line. As
part of the campaign, five lucky winners will get brighter and more
even-toned complexion with elure's comprehensive range of products
– an exclusive favorite of beauty editors. Participants can
enter to win a complete elure range of products ($335 value) to BREAK UP stubborn discoloration
and GET EVEN skin tone, just in time for the fall season.
(Logo: http://photos.prnewswire.com/prnh/20111107/NY99332LOGO
)
How?
Just LIKE the elure Facebook page
(https://www.facebook.com/elureskin) and tell elure about your
worst break up story. Include some of the dirty little details (but
not too dirty!) about why this break up was memorable. And if you
did something evil to get even, please dish! Without revealing
names or location, we want to hear how the break up happened and
what you learned from it. Share with us your thoughts on how
others can avoid their worst break up ever. The contest will run
for 28 days from October 1, 2012 to
October 28, 2012. Winners will be
announced on October 29, 2012 on
Twitter @elureskin and on Facebook www.facebook.com/elureskin.
Why 28 days?
Because 28 days is all it takes to get more even toned skin
with elure. Fans can vote for their favorites, so be sure to pick
yours.
What is elure?
elure is the first clinically proven and professionally
dispensed at home skin brightening solution developed with the
natural enzyme formulation Melanozyme™, to gently yet quickly
diminish the appearance of stubborn discoloration while correcting
uneven skin tone to reveal a brighter, more glowing complexion for
all skin types.
Earning accolades from Essence magazine and allure
magazine for the elure Night Cream and allure magazine and
InStyle magazine for the elure Lotion, the elure range of
products consists of:
- elure Lotion: A rebalancing skin lotion with Melanozyme to
brighten, soften, soothe and replenish your skin.
- elure Night Cream: Moisture rich complex with Melanozyme for a
brighter and softer skin tone.
- elure Face Wash: Gentle cleanser lathers into a rich and creamy
foam that removes dirt and dead skin debris to transform your skin
from dull to radiant.
Follow the Break Up. Get Even! contest on Twitter @elureskin and
@elurebysyneron or on Facebook at www.facebook.com/elureskin.
To enter, participants must be 18+ years old and a US
resident.
About Syneron Medical Ltd.
Syneron Medical Ltd. – a company devoted to real
technology, real science and real results – is the leading global
aesthetic device company with a comprehensive product portfolio and
a global distribution footprint. The Company's technology
enables physicians to provide advanced solutions for a broad range
of medical-aesthetic applications including body contouring, hair
removal, wrinkle reduction, rejuvenation of the skin's appearance
through the treatment of superficial benign vascular and pigmented
lesions, and the treatment of acne, leg veins and cellulite.
The Company sells its products under two distinct brands, Syneron
and Candela. The Company's aspiration and commitment to
innovation expands Syneron's offering beyond medical device into
the largest in-demand applications in beauty - skin
lightening. Founded in 2000, the corporate, R&D, and
manufacturing headquarters for Syneron Medical Ltd. are located in
Israel. Syneron also has R&D
and manufacturing operations in the US. The company markets
and services and supports its products in 86 countries. It has
offices in North America,
France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan,
and Hong Kong and distributors
worldwide. Additional information can be found at
www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future
expectations, beliefs, goals, plans or prospects constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Further, any statements
that are not statements of historical fact (including statements
containing "believes," "anticipates," "plans," "expects," "may,"
"will," "would," "intends," "estimates" and similar expressions)
should also be considered to be forward-looking statements. There
are a number of important factors that could cause actual results
or events to differ materially from those indicated by such
forward-looking statements, including the risk that the businesses
of Syneron and Candela may not be integrated successfully; the risk
that the merger transaction with Candela may involve unexpected
costs or unexpected liabilities; the risk that synergies from the
merger transaction may not be fully realized or may take longer to
realize than expected; the risk that disruptions from the merger
transaction make it more difficult to maintain relationships with
customers, employees, or suppliers; as well as the risks set forth
in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F,
and the other factors described in the filings that Syneron Medical
Ltd. makes with the SEC from time to time. If one or more of these
factors materialize, or if any underlying assumptions prove
incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results,
performance or achievements expressed or implied by these
forward-looking statements.
In addition, the statements in this document reflect the
expectations and beliefs of Syneron Medical Ltd. as of the date of
this document. Syneron Medical Ltd. anticipates that subsequent
events and developments will cause its expectations and beliefs to
change. However, while Syneron Medical Ltd. may elect to update
these forward-looking statements publicly in the future, it
specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential
impact of any future dispositions or strategic transactions that
may be undertaken. These forward-looking statements should not be
relied upon as representing Syneron Medical Ltd.'s views as of any
date after the date of this document.
About elure™
elure™ is sold as a topical cosmetic intended to beautify your
skin and cosmetics are not subject to evaluation by the FDA. All
product information provided is intended to be for informational
purposes only. The information about skin conditions provided
herein does not constitute medical or pharmaceutical advice and
should not be relied upon as a substitute for qualified medical
consultation with health professionals. Additional information can
be found at www.syneron.com.
SOURCE Syneron Medical Ltd.